Neurogene Inc. Noncash or Part Noncash Acquisition, Other Liabilities Assumed
Neurogene Inc. (NGNE) reported Noncash or Part Noncash Acquisition, Other Liabilities Assumed of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 · last filed 2025-03-24
- Neurogene Inc. noncash or part noncash acquisition, other liabilities assumed for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Neurogene Inc. noncash or part noncash acquisition, other liabilities assumed for fiscal 2023 was $10.11M.
- Neurogene Inc. noncash or part noncash acquisition, other liabilities assumed for fiscal 2022 was $0.00.
| Period end | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-24 |
| 2023-12-31 | $10.11M 10-K · filed 2025-03-24 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |